Is COCP or CORT more undervalued in 2026?

CirclFi compares Cocrystal Pharma, Inc. (COCP) and Corcept Therapeutics Incorporat (CORT) using 13 institutional-grade valuation models. COCP has a Quality of Company score of 4.3/10 while CORT scores 8.7/10.

Which is a better buy — COCP or CORT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do COCP and CORT valuations compare?

COCP at $1.13 and CORT at $68.38 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

COCP vs CORT Valuation Comparison 2026 — Intrinsic Value Analysis

COCP

Biotechnology

Cocrystal Pharma, Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$1.13

Last close

Models

8/13

Active

CORT

Biotechnology

Corcept Therapeutics Incorporat

Quality

8.7

out of 10

Value Trap

LOW

Price

$68.38

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	COCP Fair Value	COCP Upside	CORT Fair Value	CORT Upside
Bayesian DCF	Intrinsic	$0.45	-60.5%	$15.47	-77.4%
Earnings Power Value	Intrinsic	—	—	$8.28	-83.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.05	-96.4%	$7.64	-88.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for COCP vs CORT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

COCP vs CORT — Which Stock Is More Undervalued?

CORT scores higher with a 8.7/10 quality rating vs COCP's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cocrystal Pharma, Inc. (COCP) and Corcept Therapeutics Incorporat (CORT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

COCP currently trades at $1.13 with a QOC of 4.3/10, while CORT trades at $68.38 with a QOC of 8.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).